[Demonstration of the therapeutic activity of 5023 SE on intellectual and psychomotor efficacy in elderly impaired patients. Double-blind controlled study versus placebo].
A controlled double-blind drug versus placebo trial was conducted in a population of mentally impaired hospital patients divided at random into two groups. In the group treated with Duxil the level of intelligence remained stable and the mental and psychomotor performances improved, as demonstrated by the response time to sounds and colours and by the number of correct answers and errors by perseveration in the Benton's test. The improvement observed under Duxil may be ascribed to a better use of the remaining intellectual capabilities.
D000368:Aged; D015765:Almitrine; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy*; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D008606:Mental Processes / Q000187:drug effects*; D010879:Piperazines / Q000627:therapeutic use*; D011597:Psychomotor Performance / Q000187:drug effects*; D011930:Reaction Time / Q000187:drug effects; D015016:Yohimbine / Q000627:therapeutic use*
D004338:Drug Combinations; D010879:Piperazines; D015016:Yohimbine; C037558:almitrine, raubasine drug combination; D015765:Almitrine
Mise en évidence de l'activité thérapeutique du 5023 SE sur l'efficacité intellectuelle et psycho-motrice des sujets âgés détériorés. Etude contrôlée à double-insu contre placebo.